Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma

被引：18
|
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, 377-2 Ohno Higashi, Osaka 5898511, Japan
来源：
LIVER CANCER | 2018年 / 7卷 / 02期
关键词：
PHASE-3; TRIAL; DOUBLE-BLIND; SYSTEMIC THERAPY; SORAFENIB; REGORAFENIB; MULTICENTER; PLACEBO; ANGIOGENESIS; GROWTH; SAFETY;
D O I：
10.1159/000488542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：123 / 133
页数：11
相关论文
共 50 条
  • [41] Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma
    Kudo, Masatoshi
    [J]. LIVER CANCER, 2018, 7 (04) : 305 - 311
  • [42] Hepatocellular Carcinoma: Successes with Regorafenib in Second-line Therapy
    Weiss, Johannes
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (05):
  • [43] Advancements in second-line treatment research for hepatocellular carcinoma
    Sun, Ruirui
    Wu, Chenrui
    Gou, Yang
    Zhao, Yaowu
    Huang, Ping
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [44] How to Choose Second-Line Treatment for Hepatocellular Carcinoma
    Frenette, Catherine
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 726 - 729
  • [45] Preserving the Liver for Second-Line Treatment of Hepatocellular Carcinoma
    Lencioni, Riccardo
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 6 - 8
  • [46] Novel Second-Line Treatments for Hepatocellular Carcinoma: Discussion
    Frenette, Catherine T.
    Lencioni, Riccardo
    Finn, Richard S.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 12 - 13
  • [47] Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification
    Yamamoto, Makoto
    Terashima, Takeshi
    Yamashita, Tatsuya
    Seki, Akihiro
    Nakagawa, Hidetoshi
    Nio, Kouki
    Shimakami, Tetsuro
    Takatori, Hajime
    Arai, Kuniaki
    Mizukoshi, Eishiro
    Honda, Masao
    Takeuchi, Shinji
    Yamashita, Taro
    [J]. HEPATOLOGY RESEARCH, 2024, 54 (03) : 315 - 319
  • [48] Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
    Deeks, Emma D.
    [J]. TARGETED ONCOLOGY, 2019, 14 (01) : 107 - 113
  • [49] Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
    Emma D. Deeks
    [J]. Targeted Oncology, 2019, 14 : 107 - 113
  • [50] US COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO REGORAFENIB AND CABOZANTINIB IN SECOND LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
    Upadhyay, N.
    Mistry, R.
    Suri, G.
    Phelps, H.
    Guest, S.
    Muston, D.
    [J]. VALUE IN HEALTH, 2019, 22 : S73 - S74
12345